title: Histone deacetylase inhibitors specifically kill nonproliferating tumour cells.
abstract: Conventional chemotherapeutic drugs target proliferating cells, relying on often small differences in drug sensitivity of tumour cells compared to normal tissue to deliver a therapeutic benefit. Consequently, they have significant limiting toxicities and greatly reduced efficacy against nonproliferating compared to rapidly proliferating tumour cells. This lack of selectivity and inability to kill nonproliferating cells that exist in tumours with a low mitotic index are major failings of these drugs. A relatively new class of anticancer drugs, the histone deacetylase inhibitors (HDI), are selectively cytotoxic, killing tumour and immortalized cells but normal tissue appears resistant. Treatment of tumour cells with these drugs causes both G1 phase cell cycle arrest correlated with increase p21 expression, and cell death, but even the G1 arrested cells died although the onset of death was delayed. We have extended these observations using cells that were stably arrested by either serum starvation or expression of the cyclin-dependent kinase inhibitor p16(ink4a). We report that histone deacetylase inhibitors have similar cytotoxicity towards both proliferating and arrested tumour and immortalized cells, although the onset of apoptosis is delayed by 24 h in the arrested cells. Both proliferating and arrested normal cells are unaffected by HDI treatment. Thus, the histone deacetylase inhibitors are a class of anticancer drugs that have the desirable features of being tumour-selective cytotoxic drugs that are equally effective in killing proliferating and nonproliferating tumour cells and immortalized cells. These drugs have enormous potential for the treatment of not only rapidly proliferating tumours, but tumours with a low mitotic index.
authors.affiliation: Cancer Biology Program, Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia.
authors.forename: Andrew
authors.initials: A
authors.lastname: Burgess
authors.forename: Astrid
authors.initials: A
authors.lastname: Ruefli
authors.forename: Heather
authors.initials: H
authors.lastname: Beamish
authors.forename: Robyn
authors.initials: R
authors.lastname: Warrener
authors.forename: Nicholas
authors.initials: N
authors.lastname: Saunders
authors.forename: Ricky
authors.initials: R
authors.lastname: Johnstone
authors.forename: Brian
authors.initials: B
authors.lastname: Gabrielli
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects*; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000633:toxicity*; D005434:Flow Cytometry; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D007231:Infant, Newborn; D008545:Melanoma / Q000473:pathology; D012867:Skin / Q000166:cytology / Q000187:drug effects
chemical_list: D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors